Structure Therapeutics price target raised to $99 from $61 at Clear Street

Clear Street raised the firm’s price target on Structure Therapeutics (GPCR) to $99 from $61 and keeps a Buy rating on the shares. The Phase 2b Access 36-week data underscore aleniglipron’s best-in-class potential, delivering up to 15.3% placebo-adjusted weight loss and surpassing the 11.5% benchmark set by Lilly’s ( LLY) orforglipron in Phase 3 Attain-1, semaglutide’s Phase 3 STEP 1 (36 weeks), and RYBELSUS (oral semaglutide) Phase 2 results (36 weeks), . the analyst tells investors in a research note. The drug’s safety profile also remains competitive, with adverse effect-related treatment discontinuations in Access at 10.4% – comparable to Attain-1’s 10.3% at Week 72, the firm added.